KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BusinesswireOct 2 06:30 ET

Express News | Kalvista Pharmaceuticals Inc - Sebetralstat Phase 3 Trial Meets Primary Endpoint

ReutersSep 30 06:30 ET

KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema

BusinesswireSep 30 06:30 ET

Express News | Kalvista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral on-Demand Treatment of Hereditary Angioedema

ReutersSep 30 06:30 ET

KalVista Pharmaceuticals Up Over 19%, on Pace for Largest Percent Increase Since February 2021 -- Data Talk

Dow JonesSep 27 13:25 ET

KalVista Pharmaceuticals Initiated at Buy by Jones Trading

Dow JonesSep 27 09:48 ET · Ratings